With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …

Protein phosphorylation is an important post‐transcriptional modification involving an
extremely wide range of intracellular signaling transduction pathways, making it an …

The study initially determined the baseline inhibitory concentration (BIC) for ASC
monotherapy and each ABPI using the K562/WT and BaF3/WT cell lines, respectively …

Tyrosine kinase inhibitors (TKIs) have significantly changed the treatment of chronic myeloid
leukemia (CML) and improved outcomes for patients with CML in chronic phase (CML-CP) …

The article by Abdelmagid and co-authors on real-world experience with ponatinib that
accompanies this editorial is interesting. There are three points to take from this. First, it …

The introduction of imatinib in 2000 opened the era of tyrosine kinase inhibitors (TKIs) for
CML therapy and has revolutionized the life expectancy of CML patients, which is now quite …

Background Patients with chronic myeloid leukemia (CML) treated with tyrosine kinase
inhibitors (TKIs) often experience cutaneous adverse events, such as rashes and pruritus. In …

Chronic myeloid leukaemia (CML) is caused by BCR:: ABL1. Tyrosine kinase-inhibitors
(TKIs) are the initial therapy. Several organizations have reported milestones to evaluate …

Abstract Introduction Tyrosine kinase inhibitors (TKIs) have become the mainstay of
treatment for chronic myeloid leukaemia (CML), but cardiovascular (CV) risk and …

The selective RNA polymerase I inhibitor CX‑5461 has been shown to be effective in
treating some types of leukemic disorders. Emerging evidence suggests that combined …